Skip to main content

Glossary


Site Glossary

A

ADS Analytical Decision Support
AIG Anthrax Immune Globulin
AMCG Office of Acquisition Management, Contracts, & Grants
AMIC Animal Model Interagency Committee
Arenavirus The Arenaviridae are a family of viruses whose members are generally associated with rodent-transmitted diseases in humans. Each virus usually is associated with a particular rodent host species in which it is maintained.
Animal Efficacy Rule The FDA Animal Efficacy Rule (also known as Animal Rule) applies to development/testing of drugs / biologicals to reduce or prevent serious/life-threatening conditions caused by exposure to lethal /permanently disabling toxic agent (chemical, biological, radiological, or nuclear substances), where human efficacy trials are not feasible or ethical
ARS Acute Radiation Syndrome; also known as radiation poisoning, radiation sickness or radiation toxicity, is a collection of health effects which present within 24 hours of exposure to high amounts of ionizing radiation.
ASPR Assistant Secretary for Preparedness and Response

B

BAA Broad Agency Announcements
BARDA Biomedical Advanced Research and Development Authority
BPN Business Partner Network
BSA Broad Spectrum Antimicrobials

C

CAP Concept Acceleration Program
CBMS Chemical Biological Medical Systems
CBRN Chemical, Biological, Radiological and Nuclear Threats
CBRND Chemical, Biological, Radiological and Nuclear Threats Defense
CDC Center for Desease Control
CDER Center for Drug Evaluation and Research
CFR Code of Federal Regulations
CIADM Centers for Innovation in Advanced Development and Manufacturing
CLIA Clinical Laboratory Improvement Amendment
CSN Clinical Studies Network

D

DARPA Defense Advanced Research Projects Agency
DCEG Division of Cancer Epidemiology and Genetics
DCS Clinical Studies group
DHS Department of Homeland Security
DoD Department of Defense
DSMB Data Safety Monitoring Board
DTRA Defense Threat Reduction Agency

E

EID Emerging Infectious Diseases
EMS Emergency Medical Services
EUA Emergency Use Authorization

F

FAR Federal Acquisition Regulations
FD&C Federal Food, Drug and Cosmetic Act
FDA Food and Drug Administration
FedBizOpps Federal Business Opportunities
FFMN Fill Finish Manufacturing Network

G

GI Gastrointestinal
GPE Government Point-of-Entry
 
Back to top

H

HGS Human Genome Sciences
HHS U.S. Department of Health and Human Services
HHSAR Department of Health and Human Services Acquisition Regulation

I

IEDB Immune Epitope Database
IND Investigational New Drug

J

JOFOC Justification for Other than Full and Open Competition

M

MCM Medical Countermeasures
MCMi Medical Countermeasures initiative
MMWR Morbidity and Mortality Weekly Report

N

NARA National Archives and Records Administration
NBLs National Biocontainment Laboratories
NCI National Cancer Institute
NHLBI National Heart, Lung and Blood Institute
NIAID National Institute of Allergy and Infectious Diseases
NIH National Institutes of Health
NINDS National Institute of Neurological Disorders and Stroke
NSABB National Science Advisory Board for BioSecurity
 
Back to top

O

OEM Office of Emergency Management
OMB Office of Management and Budget
OPP Office of Policy and Planning

P

PAHPA The Pandemic and All Hazards Preparedness Act
PBS Project BioShield
PDTs Product Development Tools
PEP Post-Event Prophylactic
PHCM Public Health Consequence Modeling
PHEMCE Public Health Emergency Medical Countermeasures Enterprise
PHS Public Health Service

R

RBLs Regional Biocontainment Laboratories
RCE Regional Centers of Excellence
REB Radiation Epidemiology Branch
RFP Request for Proposal
RQA Division of Regulatory and Quality Affairs
RSV Respiratory Syncytial Virus
RTOR Request for Task Order Response

S

SAE Serious Adverse Event
SIP Strategy and Implementation Plan
SNS Strategic National Stockpile
SST Strategic Science and Technology

T

TICs Toxic Industrial Chemicals
TIMs Toxic Industrial Materials
TMTI Transformational Medical Technologies Initiative
TRA Terrorism Risk Assessment
TRLs Technology Readiness Levels
Website Refresh - www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov